PRAC September 2024 – Recommendation for metamizole and to minimise the risk associated with medroxyprogesterone acetate
The PRAC recommends measures to minimise serious outcomes of known side effect with the painkiller metamizole and formulated new recommendations to minimise the risk of meningioma with medicines containing medroxyprogesterone acetate.
During its September 2024 meeting, the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) recommended measures to minimise serious outcomes of known side effect with painkiller metamizole and formulated new recommendations to minimise the risk of meningioma with medicines containing medroxyprogesterone acetate.